



Published on *SWOT Analysis* (<https://www.swotanalysis.info>)

Home > Global Imatinib Mesylate Tablets Market Growth (Status and Outlook) 2022-2028

Global Imatinib Mesylate Tablets Market Growth (Status and Outlook) 2022-2028

Publication ID:

ARS0821050

Publication Date:

August 14, 2021

Pages:

97

Publisher:

Arsta

Region:

Global [1]

\$3,660.00

Publication License Type *

Single User License (PDF), \$3,660.00

Global License (PDF), \$5,860.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

As the global economy recovers in 2021 and the supply of the industrial chain improves, the Imatinib Mesylate Tablets market will undergo major changes. According to the latest research, the market

size of the Imatinib Mesylate Tablets industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.

The global Imatinib Mesylate Tablets industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.

The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Imatinib Mesylate Tablets market during the next few years. The global Imatinib Mesylate Tablets market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.

This report presents a comprehensive overview, market shares, and growth opportunities of Imatinib Mesylate Tablets market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

100 mg

400 mg

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

Hospital

Clinics

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Teva Pharmaceuticals
Hikma Pharmaceuticals
Apotex Inc
Sun Pharmaceutical Industries
Lupin Limited
Natco Pharma
Getwell Oncology

Table Of Contents:

Table of Content

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Imatinib Mesylate Tablets Market Size 2017-2028

2.1.2 Imatinib Mesylate Tablets Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Imatinib Mesylate Tablets Segment by Type

2.2.1 100 mg

2.2.2 400 mg

2.3 Imatinib Mesylate Tablets Market Size by Type

- 2.3.1 Imatinib Mesylate Tablets Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Imatinib Mesylate Tablets Market Size Market Share by Type (2017-2022)
- 2.4 Imatinib Mesylate Tablets Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinics
- 2.5 Imatinib Mesylate Tablets Market Size by Application
 - 2.5.1 Imatinib Mesylate Tablets Market Size CAGR by Application (2017 VS 2022 VS 2028)
 - 2.5.2 Global Imatinib Mesylate Tablets Market Size Market Share by Application (2017-2022)
- 3 Imatinib Mesylate Tablets Market Size by Player
 - 3.1 Imatinib Mesylate Tablets Market Size Market Share by Players
 - 3.1.1 Global Imatinib Mesylate Tablets Revenue by Players (2020-2022)
 - 3.1.2 Global Imatinib Mesylate Tablets Revenue Market Share by Players (2020-2022)
 - 3.2 Global Imatinib Mesylate Tablets Key Players Head office and Products Offered
 - 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
 - 3.4 New Products and Potential Entrants
 - 3.5 Mergers & Acquisitions, Expansion
- 4 Imatinib Mesylate Tablets by Regions
 - 4.1 Imatinib Mesylate Tablets Market Size by Regions (2017-2022)
 - 4.2 Americas Imatinib Mesylate Tablets Market Size Growth (2017-2022)
 - 4.3 APAC Imatinib Mesylate Tablets Market Size Growth (2017-2022)
 - 4.4 Europe Imatinib Mesylate Tablets Market Size Growth (2017-2022)
 - 4.5 Middle East & Africa Imatinib Mesylate Tablets Market Size Growth (2017-2022)
- 5 Americas
 - 5.1 Americas Imatinib Mesylate Tablets Market Size by Country (2017-2022)
 - 5.2 Americas Imatinib Mesylate Tablets Market Size by Type (2017-2022)
 - 5.3 Americas Imatinib Mesylate Tablets Market Size by Application (2017-2022)
 - 5.4 United States
 - 5.5 Canada
 - 5.6 Mexico
 - 5.7 Brazil
- 6 APAC
 - 6.1 APAC Imatinib Mesylate Tablets Market Size by Region (2017-2022)
 - 6.2 APAC Imatinib Mesylate Tablets Market Size by Type (2017-2022)
 - 6.3 APAC Imatinib Mesylate Tablets Market Size by Application (2017-2022)
 - 6.4 China
 - 6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Imatinib Mesylate Tablets by Country (2017-2022)

7.2 Europe Imatinib Mesylate Tablets Market Size by Type (2017-2022)

7.3 Europe Imatinib Mesylate Tablets Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Imatinib Mesylate Tablets by Region (2017-2022)

8.2 Middle East & Africa Imatinib Mesylate Tablets Market Size by Type (2017-2022)

8.3 Middle East & Africa Imatinib Mesylate Tablets Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global Imatinib Mesylate Tablets Market Forecast

10.1 Global Imatinib Mesylate Tablets Forecast by Regions (2023-2028)

10.1.1 Global Imatinib Mesylate Tablets Forecast by Regions (2023-2028)

10.1.2 Americas Imatinib Mesylate Tablets Forecast

10.1.3 APAC Imatinib Mesylate Tablets Forecast

10.1.4 Europe Imatinib Mesylate Tablets Forecast

10.1.5 Middle East & Africa Imatinib Mesylate Tablets Forecast

10.2 Americas Imatinib Mesylate Tablets Forecast by Country (2023-2028)

10.2.1 United States Imatinib Mesylate Tablets Market Forecast

10.2.2 Canada Imatinib Mesylate Tablets Market Forecast

10.2.3 Mexico Imatinib Mesylate Tablets Market Forecast

10.2.4 Brazil Imatinib Mesylate Tablets Market Forecast

10.3 APAC Imatinib Mesylate Tablets Forecast by Region (2023-2028)

10.3.1 China Imatinib Mesylate Tablets Market Forecast

10.3.2 Japan Imatinib Mesylate Tablets Market Forecast

10.3.3 Korea Imatinib Mesylate Tablets Market Forecast

10.3.4 Southeast Asia Imatinib Mesylate Tablets Market Forecast

10.3.5 India Imatinib Mesylate Tablets Market Forecast

10.3.6 Australia Imatinib Mesylate Tablets Market Forecast

10.4 Europe Imatinib Mesylate Tablets Forecast by Country (2023-2028)

10.4.1 Germany Imatinib Mesylate Tablets Market Forecast

10.4.2 France Imatinib Mesylate Tablets Market Forecast

10.4.3 UK Imatinib Mesylate Tablets Market Forecast

10.4.4 Italy Imatinib Mesylate Tablets Market Forecast

10.4.5 Russia Imatinib Mesylate Tablets Market Forecast

10.5 Middle East & Africa Imatinib Mesylate Tablets Forecast by Region (2023-2028)

10.5.1 Egypt Imatinib Mesylate Tablets Market Forecast

10.5.2 South Africa Imatinib Mesylate Tablets Market Forecast

10.5.3 Israel Imatinib Mesylate Tablets Market Forecast

10.5.4 Turkey Imatinib Mesylate Tablets Market Forecast

10.5.5 GCC Countries Imatinib Mesylate Tablets Market Forecast

10.6 Global Imatinib Mesylate Tablets Forecast by Type (2023-2028)

10.7 Global Imatinib Mesylate Tablets Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 Teva Pharmaceuticals

11.1.1 Teva Pharmaceuticals Company Information

11.1.2 Teva Pharmaceuticals Imatinib Mesylate Tablets Product Offered

11.1.3 Teva Pharmaceuticals Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 Teva Pharmaceuticals Main Business Overview

11.1.5 Teva Pharmaceuticals Latest Developments

11.2 Hikma Pharmaceuticals

11.2.1 Hikma Pharmaceuticals Company Information

11.2.2 Hikma Pharmaceuticals Imatinib Mesylate Tablets Product Offered

11.2.3 Hikma Pharmaceuticals Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Hikma Pharmaceuticals Main Business Overview

11.2.5 Hikma Pharmaceuticals Latest Developments

11.3 Apotex Inc

11.3.1 Apotex Inc Company Information

11.3.2 Apotex Inc Imatinib Mesylate Tablets Product Offered

- 11.3.3 Apotex Inc Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Apotex Inc Main Business Overview
- 11.3.5 Apotex Inc Latest Developments
- 11.4 Sun Pharmaceutical Industries
 - 11.4.1 Sun Pharmaceutical Industries Company Information
 - 11.4.2 Sun Pharmaceutical Industries Imatinib Mesylate Tablets Product Offered
 - 11.4.3 Sun Pharmaceutical Industries Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
 - 11.4.4 Sun Pharmaceutical Industries Main Business Overview
 - 11.4.5 Sun Pharmaceutical Industries Latest Developments
- 11.5 Lupin Limited
 - 11.5.1 Lupin Limited Company Information
 - 11.5.2 Lupin Limited Imatinib Mesylate Tablets Product Offered
 - 11.5.3 Lupin Limited Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
 - 11.5.4 Lupin Limited Main Business Overview
 - 11.5.5 Lupin Limited Latest Developments
- 11.6 Natco Pharma
 - 11.6.1 Natco Pharma Company Information
 - 11.6.2 Natco Pharma Imatinib Mesylate Tablets Product Offered
 - 11.6.3 Natco Pharma Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
 - 11.6.4 Natco Pharma Main Business Overview
 - 11.6.5 Natco Pharma Latest Developments
- 11.7 Getwell Oncology
 - 11.7.1 Getwell Oncology Company Information
 - 11.7.2 Getwell Oncology Imatinib Mesylate Tablets Product Offered
 - 11.7.3 Getwell Oncology Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
 - 11.7.4 Getwell Oncology Main Business Overview
 - 11.7.5 Getwell Oncology Latest Developments

12 Research Findings and Conclusion

Companies Mentioned:

Teva Pharmaceuticals

Hikma Pharmaceuticals

Apotex Inc

Sun Pharmaceutical Industries

Lupin Limited

Natco Pharma

Getwell Oncology

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is SWOT Analysis?](#)

March 12

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL:<https://www.swotanalysis.info/arsta/global-imatinib-mesyate-tablets-market-growth-status-and-outlook-2022-2028>

Links

[1] <https://www.swotanalysis.info/region/global>